New drug Alpha-0261 takes first step: safety check in healthy volunteers
NCT ID NCT07279636
First seen Jan 08, 2026 · Last updated Jun 04, 2026 · Updated 23 times
Summary
This early-stage study is testing a new drug, Alpha-0261, in 60 healthy adults aged 18 to 55. The main goal is to see if a single dose is safe and how the body processes it. No treatment is being given for any disease; this is a first step to gather safety information before testing in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bishan Hospital of Chongqing
RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.